FBLG Overview

FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

Wall Street analysts forecast FBLG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBLG is3.25 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fibrobiologics Inc revenue for the last quarter amounts to -5.07M USD, increased 11.85

Fibrobiologics Inc. EPS for the last quarter amounts to -4364000.00 USD, decreased -17.94

Fibrobiologics Inc (FBLG) has 15 emplpoyees as of July 01 2026.

Today FBLG has the market capitalization of 4.94M USD.